Information Provided By:
Fly News Breaks for August 15, 2018
IDRA
Aug 15, 2018 | 07:53 EDT
JPMorgan analyst Anupam Rama resumed coverage of Idera Pharmaceuticals with an Overweight rating and $15 price target following a period of restriction. Rama tells investors in a research note that Idera's Q2 results highlighted its continued prioritization of IMO-2125 in oncology, and views IMO-2125 as an underappreciated asset at current levels. Looking ahead, Rama believes the TLR9 space is gaining increased interest, and says date to data for IMO-2125 are differentiated in PD-1 refractory metastatic melanoma.
News For IDRA From the Last 2 Days
There are no results for your query IDRA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.